Friday 6 November 2026 Export SUPN’s income statement to Excel — free account

Indivior Pharmaceuticals Inc.

SUPN Healthcare Drug Manufacturers Specialty & Generic

Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024.

Revenue: +13.4%
EPS: +241.5%
Free cash flow: +240.7%
Total debt: +51.6%

Quarter to September 2026, against a year earlier

28.21 0.06 +0.21%

Follow SUPN

Alert me

Market cap: $5.6B
P/E: 7.6×
Fwd P/E: 9.5×
Dividend yield: 0.00%
F-score: 4/9
Altman Z: 3.28
Beneish M: −1.52
Dividend safety: n/a

Overview

Indivior Pharmaceuticals Inc. (SUPN) P/E ratio

Alert me on P/E ratio

As of 4 November 2026, Indivior Pharmaceuticals Inc. (SUPN) trades at a P/E ratio of 7.6×. Over the past ten years it has ranged from 0.0× (June 2025) to 92.0× (February 2017); the current reading is higher than 48% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 20.5× and below the Healthcare sector median of 25.2×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/SUPN/pe-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Indivior Pharmaceuticals Inc. P/E ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/SUPN/metrics/pe-ratio">Indivior Pharmaceuticals Inc. (SUPN) P/E ratio — stockrow.com</a></p>

Period	P/E ratio	Change
FY2025	21.2×	—
FY2024	0.0×	—
FY2023	0.0×	—
FY2022	0.0×	—
FY2021	12.3×	—
FY2020	0.0×	—
FY2019	2.9×	(18.68%)
FY2018	3.6×	(94.83%)
FY2017	68.8×	(3.17%)
FY2016	71.0×	727.88%

Period	P/E ratio	Change
Sep 2026	9.7×	(31.95%)
Jun 2026	14.2×	(5.91%)
Mar 2026	15.1×	(28.93%)
Dec 2025	21.2×	(9.62%)
43 more quarters	Free account

Against its own ten years

Low 0.0× High 92.0×

Ten-year median 8.6×

Current reading's percentile 21

Company	P/E ratio
HIMS Hims & Hers Health, Inc. compare	n/m
AMLX Amylyx Pharmaceuticals, Inc. compare	n/m
ALKS Alkermes plc compare	n/m
SUPN Indivior Pharmaceuticals Inc.	7.6×
LNTH Lantheus Holdings, Inc. compare	24.3×
LQDA Liquidia Corporation compare	28.5×
AMRX AMNEAL PHARMACEUTICALS, INC. compare	36.9×
RDY Dr. Reddy's Laboratories Ltd compare	44.4×
KNSA Kiniksa Pharmaceuticals International, plc compare	62.1×
Drug Manufacturers Specialty & Generic industry median	20.5×
Healthcare sector median	25.2×
Market median	17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

Indivior Pharmaceuticals Inc. (SUPN) P/E ratio

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on SUPN

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on SUPN

Stockrow Weekly